Corrigendum to: Gliptin-mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon-like peptide-1 receptor (Diabetes, Obesity and Metabolism, (2016), 18, 5, (537-541), 10.1111/dom.12641);Gliptin-mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon-like peptide-1 receptor

Diabetes, Obesity and Metabolism

Volumn 18, Issue 5, 2016, Pages 537-541

  Darsalia, V ^a   Larsson, M ^a   Lietzau, G ^a,c   Nathanson, D ^a   Nystrom T ^a   Klein, T ^b   Patrone, C ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

DPP 4 inhibitors; Gliptins; GLP 1; Linagliptin; Stroke; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; DPP4 PROTEIN, MOUSE; EXENDIN 4; GLP1R PROTEIN, MOUSE; GLUCAGON LIKE PEPTIDE 1; NERVE PROTEIN; NEUN PROTEIN, MOUSE; NEUROPROTECTIVE AGENT; NUCLEAR PROTEIN; PEPTIDE; VENOM;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN INFARCTION SIZE; BRAIN LEVEL; CELL SURVIVAL; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LETTER; LONG TERM CARE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; MOUSE MODEL; NERVE CELL; NEUROPROTECTION; NONHUMAN; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; TREATMENT DURATION; WILD TYPE; AGONISTS; ANIMAL; BLOOD; BRAIN CORTEX; CHEMISTRY; COMPARATIVE STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECTS; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; STROKE;

ADMINISTRATION, ORAL; ANIMALS; CELL SURVIVAL; CEREBRAL CORTEX; CORPUS STRIATUM; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; NUCLEAR PROTEINS; PEPTIDES; STROKE; VENOMS;

EID: 84960910536     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13201     Document Type: Erratum

References (16)

1. Patrone C, Eriksson O, Lindholm D. Diabetes drugs and neurological disorders: new views and therapeutic possibilities. Lancet Diabetes Endocrinol 2014; 2: 256-262.
2. Scheen AJ. A review of gliptins for 2014. Expert Opin Pharmacother 2015; 16: 43-62.
3. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011; 13: 7-18.
4. Tziomalos K, Bouziana SD, Spanou M etal. Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus admitted with acute ischaemic stroke. Diab Vasc Dis 2015; 12: 463-466.
5. Darsalia V, Ortsater H, Olverling A etal. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes 2013; 62: 1289-1296.
6. Yang D, Nakajo Y, Iihara K, Kataoka H, Yanamoto H. Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice. Brain Res 2013; 1517: 104-113.
7. Darsalia V, Larsson M, Nathanson D, Klein T, Nystrom T, Patrone C. Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke. J Cereb Blood Flow Metab 2015; 35: 718-723.
8. Han L, Holscher C, Xue GF, Li G, Li D. A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat. Neuroreport 2016; 27: 23-32.
9. Nicolai J, Burbassi S, Rubin J, Meucci O. CXCL12 inhibits expression of the NMDA receptor's NR2B subunit through a histone deacetylase-dependent pathway contributing to neuronal survival. Cell Death Dis 2010; 1: e33.
10. Ohtaki H, Nakamachi T, Dohi K etal. Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. Proc Natl Acad Sci U S A 2006; 103: 7488-7493.
11. Scrocchi LA, Brown TJ, MaClusky N et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996; 2: 1254-1258.
12. Ma M, Hasegawa Y, Koibuchi N etal. DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice. Cardiovasc Diabetol 2015; 14: 54.
13. Kim NH, Yu T, Lee DH. The nonglycemic actions of dipeptidyl peptidase-4 inhibitors. BioMed Res Int 2014; 2014: 368703.
14. Sharkovska Y, Reichetzeder C, Alter M etal. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. J Hypertens 2014; 32: 2211-2223; discussion 23.
15. Fuchs H, Binder R, Greischel A. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharm Drug Dispos 2009; 30: 229-240.
16. Kroller-Schon S, Knorr M, Hausding M etal. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res 2012; 96: 140-149.